Companies /Healthcare
Adc Therapeutics SA
NYSE: ADCT Drug Manufacturers - Specialty & Generic
$1.43
▼ $0.28 (−16.18%) today
Markets open · 3:06pm ET

ADC Therapeutics (ADCT) Q1 2026 Earnings

Reported May 4, 2026, 7:43am ET · SEC source
$-0.13
Beat +35.55%
EPS · est. $-0.20
$20.9M
Beat +4.32%
Revenue · est. $20.0M
−69.6%
Trailing market
ADCT vs S&P since report
4 quarters
Consecutive EPS beats

How Did ADCT Stock React to Q1 2026 Earnings?

% change · around the report
−4%0+4%+8%May 4May 5report 7:43am ETearnings+0.7%−2.8%
−4%0+4%+8%May 4May 5earnings+0.7%−2.8%
ADCT −2.8%S&P 500 +0.7%
−4%0+4%+8%May 4May 5report 7:43am ETearnings+1.3%−2.8%
−4%0+4%+8%May 4May 5earnings+1.3%−2.8%
ADCT −2.8%NASDAQ +1.3%
−5%0+5%+10%May 4May 12report 7:43am ETearnings+2.5%−6.7%
−5%0+5%+10%May 4May 12earnings+2.5%−6.7%
ADCT −6.7%S&P 500 +2.5%
−5%0+5%+10%May 4May 12report 7:43am ETearnings+5.1%−6.7%
−5%0+5%+10%May 4May 12earnings+5.1%−6.7%
ADCT −6.7%NASDAQ +5.1%
−3.92%
Day of report
+2.17%
Next session
−5.43%
One week
−64.13%
30 days

S&P 500 over the same 30 days: +5.44%.

Did ADCT Beat Earnings? Q1 2026 Results

Yes. ADC Therapeutics reported Q1 2026 earnings of $-0.13 a share on May 4, 2026, beating the $-0.20 consensus estimate by 35.5%. Revenue was $20.9M against a $20.0M estimate.

ADC Therapeutics delivered a stronger-than-expected first quarter for fiscal 2026, posting a loss of $0.13 per share against a consensus estimate of $0.20, a beat of 35.55%, while revenue of $20.85 million edged past the $19.99 million analyst forecast by 4.32%. Total revenue fell 9.5% year over year, largely because the prior-year period included a one-time partner milestone that inflated license revenues; stripping that out, net product revenues for ZYNLONTA grew 15% to $20.03 million, reflecting higher pricing and stronger unit volumes. The narrower loss was also driven by a $9.05 million reduction in R&D expenses as discontinued programs and completed IND-enabling work lowered external costs. Management maintained its cash runway guidance of at least into 2028, with $231.01 million on hand, and investors are closely watching for topline data from the LOTIS-5 Phase 3 confirmatory trial, expected by the end of June, which could support an sBLA submission before year-end and potentially unlock a significantly broader addressable market for ZYNLONTA across B-cell malignancies.

Key Takeaways
  • ZYNLONTA product revenue growth driven by higher volume and pricing
  • R&D expense reduction of $9 million due to discontinued programs and completed IND-enabling activities
  • Personnel cost reallocation from R&D to commercial manufacturing and selling activities

“During the first quarter, we continued to build momentum across our ZYNLONTA program. Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in the second quarter, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA's role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027.”

ADC Therapeutics CEO, on the earnings call

What Was ADC Therapeutics's Outlook in Q1 2026?

ADC Therapeutics expects LOTIS-5 Phase 3 topline results in Q2 2026, with full results from both LOTIS-5 and LOTIS-7 anticipated by year-end 2026. If LOTIS-5 is positive, the company intends to submit an sBLA to the FDA before year-end, targeting potential compendia inclusion in H1 2027 and confirmatory approval in 2L+ DLBCL thereafter. Investigator-initiated trial data in follicular lymphoma and marginal zone lymphoma are expected between late 2026 and mid-2027. The company projects cash runway at least into 2028 and anticipates accelerating its growth trajectory starting in 2027.

ADCT YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$-20,000,000$0$20.0M$23.0M$20.9MRevenue$21.0M$17.2MGross Profit$-22,679,903$-25,245,000Operating Income$-28,767,888$-32,968,000Net Income
$-20,000,000$0$20.0MRevenueGross ProfitOperating IncomeNet Income
ADCT income statement, Q1 2026 versus Q1 2025
Metric Q1 2026 Q1 2025 Year over year
Revenue $20.9M $23.0M −9.5%
Gross Profit $17.2M $21.0M −17.8%
Operating Income −$25.2M −$22.7M +11.3%
Net Income −$33.0M −$28.8M +14.6%

ADCT Revenue by Segment

ZYNLONTA (Product Revenue)
ZYNLONTA Product Revenue$20.0M
ZYNLONTA
ZYNLONTA (Product Revenues)
License Revenues and Royalties$818,000

Figures from SEC filings and company reports. Not investment advice.